Therapeutic observation of grain-sized moxibustion for chemotherapy-induced myelosuppression for non-small cell lungcancer
- VernacularTitle:麦粒灸对非小细胞肺癌化疗后骨髓抑制的疗效观察
- Author:
Guan-Ai BAO
;
Wei-Bin DU
;
Chen WANG
;
Ying-Nan JIN
- Keywords:
Acupuncture-moxibustion Therapy;
Moxibustion Therapy;
Moxibustion with Grain-sized Moxa Cone;
Lung Neoplasms;
Chemoradiotherapy;
Drug-related Side Effects and Adverse Reaction;
Myelosuppression;
Quality of Life
- From:
Journal of Acupuncture and Tuina Science
2019;17(4):239-244
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the clinical efficacy of grain-sized moxibustion in treating chemotherapy-induced myelosuppression for non-small cell lung cancer (NSCLC) and its effect on quality of life (QOL). Methods: Eighty NSCLC patients admitted to the Inpatient Department of Zhejiang Cancer Hospital between September 2016 and March 2018 were recruited and divided into an observation group and a control group by random number method, with 40 cases in each group. The two groups both received chemotherapy with paclitaxel plus cisplatin (TP regimen). The control group received oral administration of leucogen tablets starting from the first day of chemotherapy, 20 mg each time, three times a day, for consecutive 14 d; the observation group was additionally given grain-sized moxibustion, once a day, five days per week at a two-day interval, until the fourteenth day. The myelosuppression severity was observed and compared between the two groups prior to chemotherapy, at the 3rd, 7th and 14th days of chemotherapy; the QOL in the two groups was evaluated before chemotherapy, at the 14th and 21st days of chemotherapy. Results: Regarding myelosuppression, the peripheral blood indicators increased significantly at the 3rd day of chemotherapy in both groups (P<0.05 or P<0.01); at the 7th and 14th days of chemotherapy, the peripheral blood indicators presented a decreasing tendency in the two groups, but the level in the observation group was still significantly higher than that before chemotherapy (P<0.01); at the 3rd, 7th and 14th days of chemotherapy, the peripheral blood indicators in the observation group were higher than those in the control group (P<0.05 or P<0.01); the occurrence rate of myelosuppression in the observation group was significantly lower than that in the control group (P<0.01). The QOL score in the observation group was markedly higher than that in the control group at the 14th and 21st days of chemotherapy (both P<0.05). Conclusion: Grain-sized moxibustion can effectively improve myelosuppression after chemotherapy for NSCLC, reducing its occurrence and enhancing the patient's QOL.
